f5 Therapeutics Inc Launches Scientific Advisory Board with the Appointment of Dr. Paul Pockros

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

f5 Therapeutics Incorporated, a privately-held pharmaceutical company developing small-molecule protein degraders via the NExMods platform, today announced the appointment of Paul Pockros, MD to its Scientific Advisory Board.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, February 10, 2022
Information
Tags: 
Research, Finance, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Liver disease, Alcoholism, Factor X, Protein, Cirrhosis, Chair, Internal medicine, Division, NASH, Leadership, Scripps, Therapy, Inflammation, 2021 Essex County Council election, Neurodegeneration, Liver transplantation, Patient, Coronavirus Scientific Advisory Board (Turkey), Clinical research, University, Non-alcoholic fatty liver disease, Founder, CEO, Liver cancer, Gastroenterology, Physician, Disease, Liver, MD, Fibrosis, Drug discovery, LLC, Pharmaceutical industry, Dietary supplement
⚠ generated by AI ↴
Organisation: 
F5 THERAPEUTICS INCORPORATED
Summary
Key Points: 
  • f5 Therapeutics Incorporated, a privately-held pharmaceutical company developing small-molecule protein degraders via the NExMods platform, today announced the appointment of Paul Pockros, MD to its Scientific Advisory Board.
  • We are excited to begin building our Scientific Advisory Board with Dr. Pockros as our founding member, said Gary Choy, Co-Founder, Chair, and CEO of f5 Therapeutics Inc He has been a pioneer in the development of multiple innovative therapies helping to improve liver disease outcomes.
  • I am excited to contribute to the mission of f5 Therapeutics, said Dr. Pockros, Protein degradation offers the ability to target previously undruggable disease driving proteins, such as transcription factors.
  • In addition to his clinical practice, Dr. Pockros is a principal investigator for a number of studies at Scripps.


f5 Therapeutics Incorporated, a privately-held pharmaceutical company developing small-molecule protein degraders via the NExMods™ platform, today announced the appointment of Paul Pockros, MD to its Scientific Advisory Board. He is the President and Founder of SC Liver Research Consortium, LLC, an organization of physicians specializing in clinical research that focuses on Phase I-IV clinical hepatology, gastroenterology, and oncology trials. Dr. Pockros has held numerous leadership roles in his distinguished career at Scripps Clinic including Director of the Liver Disease Center and Director of Clinical Research of the Scripps Translational Science Institute, Chief of Staff at Scripps Green Hospital, Medical Director of the Liver Transplantation Program, and Head of the Division of Gastroenterology/Hepatology.

“We are excited to begin building our Scientific Advisory Board with Dr. Pockros as our founding member,” said Gary Choy, Co-Founder, Chair, and CEO of f5 Therapeutics Inc “He has been a pioneer in the development of multiple innovative therapies helping to improve liver disease outcomes.”

“I am excited to contribute to the mission of f5 Therapeutics,” said Dr. Pockros, “Protein degradation offers the ability to target previously undruggable disease driving proteins, such as transcription factors. This novel approach may unlock the potential for better therapeutics targeting liver cancer, liver fibrosis, and NASH. I look forward to working with f5’s team to optimize their platform technology.”

In addition to his clinical practice, Dr. Pockros is a principal investigator for a number of studies at Scripps. He has contributed over 300 published manuscripts and abstracts in peer-reviewed journals on topics such as chronic viral hepatitis, liver transplantation, complications of cirrhosis, diagnostic tests for liver disorders, and alcoholic, metabolic, and fatty liver diseases. Dr. Pockros received his medical degree and completed his residency in internal medicine at the University of Southern California School of Medicine, followed by a fellowship in hepatology at Rancho Los Amigos Medical School and a fellowship in gastroenterology at Scripps Clinic.

About f5 Therapeutics Incorporated

f5 Therapeutics is a privately held pharmaceutical company dedicated to the development of “First-in-Class” small molecules for the treatment of diseases with high unmet medical need. f5 Therapeutics continues to evolve targeted protein degradation to transform the landscape of drug discovery by utilizing the cell’s normal protein regulation systems to remove disease causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (Neosubstrate Expression Modulators) represents a novel approach to “molecular glues” capable of delivering impactful medicines to patients across diverse therapeutic areas including oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration. To learn more: http://www.f5therapeutics.com

Related Links

http://www.f5therapeutics.com

Copyright: 
Copyright Business Wire 2022